Cumberland Pharma reports Q3 net loss of $1.9M; YTD revenue up 12% to $30.8M

CUMBERLAND PHARMACEUTICALS INC

2025-Q3 EPS reported -$0.10 revenue$30,842,780

Net revenue for Q3 2025 was $8.3M; YTD $30.8M (+12% vs. 2024).
Net loss Q3 $1.9M; YTD net loss $1.4M. Adjusted loss Q3 $0.8M ($0.06/sh); adjusted earnings YTD $1.9M ($0.13/sh).
Added Talicia via joint venture with RedHill: Cumberland invests $4M for 30% ownership; net revenue split equally.
Vibativ launched in Saudi Arabia; ibuprofen injection approved in Mexico; Vibativ available through Vizient.
Ifetroban Phase II DMD showed 5.4% cardiac improvement; Phase II SSc enrollment complete; IPF trial enrolling.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.